Literature DB >> 20708226

Lymphadenectomy during endometrial cancer staging: practice patterns among gynecologic oncologists.

Pamela T Soliman1, Michael Frumovitz, Whitney Spannuth, Marilyn J Greer, Sheena Sharma, Kathleen M Schmeler, Pedro T Ramirez, Charles F Levenback, Lois M Ramondetta.   

Abstract

OBJECTIVES: Several controversies surround lymphadenectomy for endometrial cancer; surgical approach, who to stage, and the anatomic borders of the lymphadenectomy. The purpose of this study was to identify practice patterns among gynecologic oncologists when performing a lymph node evaluation during staging for endometrial cancer.
METHODS: A self-administered survey was sent via email to all SGO members on 3 occasions between 2/09 and 4/09. The survey addressed surgical approach, algorithms used to determine staging, and anatomic landmarks defining lymphadenectomy.
RESULTS: Four hundred and six members (40%) responded. Eighty-two percent completed fellowship and 14% were fellows. Thirty-four percent finished fellowship in 2000 or later. Eighty-five percent educate fellows/residents in either academic (65%) or private practice settings (20%). For a majority of cases 40% prefer laparotomy, 31% perform robotic surgery, and 29% use laparoscopy. Minimally invasive surgery was associated with university-based practice (p=0.048). Most (53%) never/rarely use frozen section to determine whether or not to perform lymphadenectomy. A majority perform staging on all grade 2 and grade 3 cancers (66% and 90%, respectively). When performing paraaortic lymphadenectomy, 50% of respondents use the IMA as the upper border and 11% take the dissection to the renal vessels. Participants who completed fellowship in 2000 or later were less likely to go to the renal vessels (p=0.002).
CONCLUSION: Current controversies in surgical staging for endometrial cancer are reflected in the practice patterns among gynecologic oncologists. At this point it is unclear if standardizing surgical practice patterns will improve outcomes for patients with endometrial cancer.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20708226      PMCID: PMC4264592          DOI: 10.1016/j.ygyno.2010.07.011

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  17 in total

1.  Revised FIGO staging for carcinoma of the endometrium.

Authors:  William Creasman
Journal:  Int J Gynaecol Obstet       Date:  2009-04-03       Impact factor: 3.561

2.  Cancer statistics, 1987.

Authors:  E Silverberg; J Lubera
Journal:  CA Cancer J Clin       Date:  1987 Jan-Feb       Impact factor: 508.702

3.  Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary?

Authors:  A Mariani; M J Webb; G L Keeney; M G Haddock; G Calori; K C Podratz
Journal:  Am J Obstet Gynecol       Date:  2000-06       Impact factor: 8.661

4.  Significance of true surgical pathologic staging: a Gynecologic Oncology Group Study.

Authors:  W T Creasman; K DeGeest; P J DiSaia; R J Zaino
Journal:  Am J Obstet Gynecol       Date:  1999-07       Impact factor: 8.661

5.  Frozen section analyses as predictors of lymphatic spread in patients with early-stage uterine cancer.

Authors:  Michael Frumovitz; Brian M Slomovitz; Diljeet K Singh; Russell R Broaddus; Jacki Abrams; Charlotte C Sun; Michael Bevers; Diane C Bodurka
Journal:  J Am Coll Surg       Date:  2004-09       Impact factor: 6.113

6.  What is the optimal minimally invasive surgical procedure for endometrial cancer staging in the obese and morbidly obese woman?

Authors:  Paola A Gehrig; Leigh A Cantrell; Aaron Shafer; Lisa N Abaid; Alberto Mendivil; John F Boggess
Journal:  Gynecol Oncol       Date:  2008-08-09       Impact factor: 5.482

7.  Robotic hysterectomy and pelvic-aortic lymphadenectomy for endometrial cancer.

Authors:  Leigh G Seamon; David E Cohn; Debra L Richardson; Sue Valmadre; Matthew J Carlson; Gary S Phillips; Jeffrey M Fowler
Journal:  Obstet Gynecol       Date:  2008-12       Impact factor: 7.661

8.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

9.  Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging.

Authors:  Andrea Mariani; Sean C Dowdy; William A Cliby; Bobbie S Gostout; Monica B Jones; Timothy O Wilson; Karl C Podratz
Journal:  Gynecol Oncol       Date:  2008-03-04       Impact factor: 5.482

10.  Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2.

Authors:  Joan L Walker; Marion R Piedmonte; Nick M Spirtos; Scott M Eisenkop; John B Schlaerth; Robert S Mannel; Gregory Spiegel; Richard Barakat; Michael L Pearl; Sudarshan K Sharma
Journal:  J Clin Oncol       Date:  2009-10-05       Impact factor: 44.544

View more
  33 in total

1.  Survival advantage of lymphadenectomy in endometrial cancer.

Authors:  Holm Eggemann; Tanja Ignatov; Katharina Kaiser; Elke Burger; Serban Dan Costa; Atanas Ignatov
Journal:  J Cancer Res Clin Oncol       Date:  2016-01-08       Impact factor: 4.553

2.  Nodal metastasis risk in endometrioid endometrial cancer.

Authors:  Michael R Milam; James Java; Joan L Walker; Daniel S Metzinger; Lynn P Parker; Robert L Coleman
Journal:  Obstet Gynecol       Date:  2012-02       Impact factor: 7.661

3.  Prospective assessment of the prevalence of pelvic, paraaortic and high paraaortic lymph node metastasis in endometrial cancer.

Authors:  Sanjeev Kumar; Karl C Podratz; Jamie N Bakkum-Gamez; Sean C Dowdy; Amy L Weaver; Michaela E McGree; William A Cliby; Gary L Keeney; Gillian Thomas; Andrea Mariani
Journal:  Gynecol Oncol       Date:  2013-10-09       Impact factor: 5.482

4.  Extent of lymphovascular space invasion may predict lymph node metastasis in uterine serous carcinoma.

Authors:  Yushen Qian; Erqi L Pollom; Chika Nwachukwu; Kira Seiger; Rie von Eyben; Ann K Folkins; Elizabeth A Kidd
Journal:  Gynecol Oncol       Date:  2017-07-11       Impact factor: 5.482

5.  Survival of Patients with Uterine Carcinosarcoma Undergoing Sentinel Lymph Node Mapping.

Authors:  Maria B Schiavone; Oliver Zivanovic; Qin Zhou; Mario M Leitao; Douglas A Levine; Robert A Soslow; Kaled M Alektiar; Vicky Makker; Alexia Iasonos; Nadeem R Abu-Rustum
Journal:  Ann Surg Oncol       Date:  2015-05-21       Impact factor: 5.344

6.  Ultrastaging of negative pelvic lymph nodes to decrease the true prevalence of isolated paraaortic dissemination in endometrial cancer.

Authors:  Francesco Multinu; Jvan Casarin; Serena Cappuccio; Gary L Keeney; Gretchen E Glaser; William A Cliby; Amy L Weaver; Michaela E McGree; Stefano Angioni; Gavino Faa; Mario M Leitao; Nadeem R Abu-Rustum; Andrea Mariani
Journal:  Gynecol Oncol       Date:  2019-05-22       Impact factor: 5.482

Review 7.  The role of para-aortic lymphadenectomy in endometrial cancer.

Authors:  Mariam M AlHilli; Andrea Mariani
Journal:  Int J Clin Oncol       Date:  2013-02-15       Impact factor: 3.402

8.  How low is low enough? Evaluation of various risk-assessment models for lymph node metastasis in endometrial cancer: a Korean multicenter study.

Authors:  Sokbom Kang; Jong-Min Lee; Jae-Kwan Lee; Jae Weon Kim; Chi-Heum Cho; Seok-Mo Kim; Sang-Yoon Park; Chan-Yong Park; Ki-Tae Kim
Journal:  J Gynecol Oncol       Date:  2012-09-19       Impact factor: 4.401

9.  Sentinel lymph node mapping with pathologic ultrastaging: a valuable tool for assessing nodal metastasis in low-grade endometrial cancer with superficial myoinvasion.

Authors:  Christine H Kim; Fady Khoury-Collado; Emma L Barber; Robert A Soslow; Vicky Makker; Mario M Leitao; Yukio Sonoda; Kaled M Alektiar; Richard R Barakat; Nadeem R Abu-Rustum
Journal:  Gynecol Oncol       Date:  2013-10-04       Impact factor: 5.482

10.  Patterns of FIRST recurrence of stage IIIC1 endometrial cancer with no PARAAORTIC nodal assessment.

Authors:  Alessia Aloisi; João Miguel Casanova; Jill H Tseng; Kristina A Seader; Nancy Thi Nguyen; Kaled M Alektiar; Vicky Makker; Sarah Chiang; Robert A Soslow; Mario M Leitao; Nadeem R Abu-Rustum
Journal:  Gynecol Oncol       Date:  2018-10-02       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.